Undisclosed FGF-1 Parkinson therapeutic / Zhittya Genesis Medicine - LARVOL DELTA

Zhittya Genesis Medicine Announces: Landmark fMRI Study Reveals 21.2% Boost in Brain Blood Flow in Parkinson’s Patient Following Six Months of Intranasal FGF-1 Therapy (GlobeNewswire) - P=NA | N=NA | "In what could be one of the most significant medical breakthroughs in the treatment of Parkinson’s disease to date, Zhittya Genesis Medicine today announced the results of a groundbreaking fMRI study that showed a 21.2% increase in brain blood flow in a Parkinson’s patient after just six months of intranasal FGF-1 therapy....Functional magnetic resonance imaging (fMRI), conducted in collaboration with researchers at Washington University School of Medicine in St. Louis, revealed stunning before-and-after images showcasing the effects of intranasal FGF-1. Regions previously marked by dangerously low blood flow showed significant improvement, and these changes correlated directly with the patient’s physical health—culminating in a 50% improvement in motor skills as measured by standardized clinical tests."

Clinical data • Parkinson's Disease

Zhittya Genesis Medicine announces: Free Zoom Webinar: Zhittya Parkinson’s Disease Research Study: 6-Month Patient Follow-Up Report (GlobeNewswire) - P1 | N=4 | NCT05493462 | Zhittya Genesis Medicine, Inc. | "Zhittya Genesis Medicine, Inc...announced that they will be hosting a webinar on Tuesday, December 20, 2022, at 4:00 PM Pacific Time / 7:00 PM Eastern, presenting data on the first Parkinson’s Disease patients dosed with FGF-1 in May 2022, who have reached their 6-month follow-up examinations. Dr. Jacobs will be presenting the medical outcomes of the patients, including safety, cognitive, and motor skill changes at the webinar....Analysis of motor scores indicates that the human test subjects had an 18-82% improvement in their motor skills. Zhittya’s study utilized their human FGF-1 biological drug candidate in conjunction with a proprietary intranasal delivery device to introduce its medicine into the brain....Analysis of videos, patient surveys, and observations from the principal investigator show promising signs of motor and cognitive improvement."

P1 data • CNS Disorders • Parkinson's Disease

Zhittya Genesis Medicine - Parkinson’s Disease and Other Brain Disorders: Is FGF-1 a Novel Breakthrough Medical Treatment (GlobeNewswire) - "Zhittya Genesis Medicine, Inc...announced it is hosting an informational luncheon presentation in Jeddah, the Kingdom of Saudi Arabia about its medical discoveries for the treatment of Parkinson’s disease. The presentation will focus on Zhittya’s possible novel treatment for growing new blood vessels in ischemic areas of the brain in an attempt to revascularize areas of the brain that are lacking sufficient blood flow. In rodent and primate models of Parkinson’s disease, this revascularization has led to the regeneration of new dopamine-secreting neurons and significant improvement in the animals’ motor skill scores. Zhittya is now receiving positive human data from their most recent medical research studies suggesting that motor scores of these Parkinson’s disease patients have improved 29%-53% after FGF-1 treatment. In addition, no adverse effects of the treatment have been noted to date."

Preclinical • CNS Disorders • Parkinson's Disease

Intranasal Human FGF-1 for Subjects With Parkinson's Disease (clinicaltrials.gov) - P1 | N=4 | Not yet recruiting | Sponsor: Zhittya Genesis Medicine, Inc.

New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease